What was Zoetis's revenue growth in the reported period?

For the nine months ended September 30, 2019, Zoetis reported an 8% increase in revenue to $4.59 billion, representing 11% operational growth when excluding the impact of foreign exchange. For the three months ended September 30, 2019, revenue increased by 7% to $1.58 billion, with operational growth of 9%.

How did the Abaxis acquisition impact the financial results?

The acquisition of Abaxis, completed in July 2018, contributed to revenue growth in both the nine-month and three-month periods ended September 30, 2019. Specifically, it contributed approximately 4% to the year-to-date revenue growth and 2% to the third-quarter revenue growth. Amortization of intangible assets also increased significantly due to this acquisition.

What are the key drivers of growth for Zoetis?

Growth is driven by several factors, including increased volume from in-line products (particularly in dermatology), volume growth from new products, price increases, and contributions from acquisitions like Abaxis. The companion animal segment, especially in the U.S., has been a significant growth engine.

What challenges did Zoetis face during this period?

Zoetis faced challenges including unfavorable foreign exchange rates, which decreased reported revenue growth. In the international segment, the livestock business was negatively impacted by the ongoing African Swine Fever outbreak, particularly in China and other Asian markets. There were also mentions of tariffs on certain products and a change in inventory costing estimate.

ZTS 10-Q Filed Nov 7, 2019

Summary

Zoetis Inc. reported strong financial results for the nine months ended September 30, 2019, with revenue increasing by 8% to $4.59 billion and net income attributable to Zoetis Inc. rising by 3% to $1.12 billion, or $2.31 per diluted share. The third quarter also demonstrated robust performance, with a 7% increase in revenue to $1.58 billion and a 25% surge in net income to $433 million ($0.90 per diluted share). The company's growth was driven by a balanced performance across its segments, with significant contributions from companion animal products, particularly in the U.S. market. The strategic acquisition of Abaxis in July 2018 continued to positively impact diagnostics revenue. Despite some headwinds from foreign exchange fluctuations and challenges in the livestock sector (notably African Swine Fever impacting certain international markets), Zoetis maintained healthy operational growth. Key financial health indicators remained strong, with substantial cash and cash equivalents and a well-managed debt structure. The company also continued its share repurchase program, demonstrating a commitment to returning value to shareholders.

Key Highlights

1Revenue for the nine months ended September 30, 2019, increased 8% to $4.59 billion, with operational growth of 11%.
2Net income attributable to Zoetis Inc. for the nine months ended September 30, 2019, was $1.12 billion, a 3% increase over the prior year.
3Diluted EPS for the nine months ended September 30, 2019, was $2.31, up from $2.22 in the prior year.
4The U.S. segment showed strong performance, with revenue up 13% year-to-date, driven by companion animal products.
5International segment revenue grew 1% year-to-date, with companion animal products showing strong growth offsetting declines in livestock due to African Swine Fever impacts.
6The company had $1.815 billion in cash and cash equivalents as of September 30, 2019.
7Zoetis continues to invest in R&D, with R&D expenses increasing 6% for the nine-month period.

Zoetis Inc. Quarterly Report for Q3 Ended Sep 30, 2019

Summary

Key Highlights

Frequently Asked Questions